Ad
AFMD Quote Trading Chart Affimed N.V.
home / stock / afmd / afmd quote
Quote | Affimed N.V. (NASDAQ:AFMD)
| Last: | $0.90 |
|---|---|
| Change Percent: | -2.34% |
| Open: | $0.92 |
| Close: | $0.90 |
| High: | $0.92 |
| Low: | $0.8875 |
| Volume: | 51,451 |
| Last Trade Date Time: | 03/18/2025 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
AFMD Last Twenty Trading Days
| Last | Open | Close | High | Low | Volume | Date |
|---|---|---|---|---|---|---|
| $0.9 | $0.92 | $0.9 | $0.92 | $0.8875 | 51,451 | 03-18-2025 |
| $0.899 | $0.89 | $0.899 | $0.979 | $0.87 | 127,216 | 03-17-2025 |
| $0.88 | $0.89 | $0.88 | $0.898 | $0.85 | 84,291 | 03-14-2025 |
| $0.876 | $0.9 | $0.876 | $0.904199 | $0.857 | 55,192 | 03-13-2025 |
| $0.89 | $0.89 | $0.89 | $0.915 | $0.8721 | 187,200 | 03-12-2025 |
| $0.907 | $0.918 | $0.907 | $0.93 | $0.85 | 132,569 | 03-11-2025 |
| $0.92495 | $0.99 | $0.92495 | $1.01 | $0.9099 | 133,664 | 03-10-2025 |
| $0.992 | $0.99 | $0.992 | $1.03 | $0.954 | 25,351 | 03-07-2025 |
| $0.99 | $1.01 | $0.99 | $1.01 | $0.960052 | 59,780 | 03-06-2025 |
| $1.03 | $0.99 | $1.03 | $1.03 | $0.96 | 37,358 | 03-05-2025 |
| $0.977 | $1 | $0.977 | $1 | $0.95 | 83,883 | 03-04-2025 |
| $0.9975 | $1.04 | $0.9975 | $1.04 | $0.97 | 67,085 | 03-03-2025 |
| $1.03 | $1.03 | $1.03 | $1.04 | $1.01 | 29,228 | 02-28-2025 |
| $1.04 | $1.06 | $1.04 | $1.06 | $1.0027 | 39,836 | 02-27-2025 |
| $1.05 | $1.01 | $1.05 | $1.05 | $1 | 77,913 | 02-26-2025 |
| $0.9957 | $1.01 | $0.9957 | $1.02 | $0.98 | 69,739 | 02-25-2025 |
| $1.02 | $1.05 | $1.02 | $1.05 | $0.998 | 33,232 | 02-24-2025 |
| $1.04 | $1.02 | $1.04 | $1.05 | $1 | 64,673 | 02-21-2025 |
| $1.02 | $1.06 | $1.02 | $1.06 | $1 | 76,265 | 02-20-2025 |
| $1.06 | $1.05 | $1.06 | $1.0899 | $1.05 | 71,798 | 02-19-2025 |
News, Short Squeeze, Breakout and More Instantly...
Affimed N.V. Company Name:
AFMD Stock Symbol:
NASDAQ Market:
-2.34% G/L:
$0.90 Last:
51,451 Volume:
$0.92 Open:
$0.90 Close:
Affimed N.V. Website:
Ad
-
MANNHEIM, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Of...
-
In 33 heavily pretreated NSCLC EGFR wild-type ( EGFR wt) patients the combination of AFM24 and atezolizumab shows an overall response rate (ORR) of 21% (6 confirmed responses, 1 response awaiting confirmatory scan) and a disease control rate (DCR) of 76%; tumor shrinkage was observed in 4...
-
AFM28, a bispecific, tetravalent innate cell engager (ICE ® ) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated R/R AML patients AFM28 demonstrates a favorable safety profile: Grade 1 and 2 Infu...